Friday 18 July 2025
  • About
  • Contact
  • Login
  • VC & Investment
  • M&A
  • AI
  • Podcasts
  • News
    • Pharmaceutical News
    • Biotechnology News
    • Generics News
    • Biosimilars news
    • In Brief
    • Legal
    • Company Pages
    • In The Boardroom
  • Insights
    • Analysis
    • Special Report
    • Interviews
    • Expert View
    • From Our Correspondent
    • One To Watch Companies
    • Digital Pharma
    • Pharma Leaders
  • Regulatory
    • FDA
    • EMA
    • Pricing, Reimbursement and Access
    • Regulation
    • Government Affairs
    • Trump Administration
  • Therapy Areas
    • Dermatologicals
    • Oncology
    • Neurological
    • Rare Diseases
    • Hematology
    • Cardio Vascular
    • Diabetes
    • Cell And Gene Therapy
  • Conferences
    • JPM Healthcare Conference
    • ESMO
    • ASCO
    • ASH
    • EULAR
    • AAIC
    • EASD
    • Forthcoming Events
  • Ones to Watch
  • About
  • Contact
  • Newsletter
  • Sign inSubscribe
Subscribe
  • Home
  • B-MS' 1st qtr hit by tax and legal costs

B-MS' 1st qtr hit by tax and legal costs

28 April 2009

US drug major Bristol-Myers Squibb's first-quarter 2009 profit fell 3.5% year-on-year to $638.0 million, despite a 3% rise in revenue to $5.02  billion, due to higher taxes and a heavy litigation charge.

The company made a one-off payment of $104.0 million, largely to settle  a shareholder law suit, while restructuring charges more than doubled to  $27.0 million.

Despite a difficult market environment, in February, B-MS made $800.0  million by selling a 17% stake in its Mead Johnson Nutrition business.  The firm retains 83% owner-ship, to help diversify risk while enhancing  management focus on biopharmaceuticals.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Try before you buy

 

Free

7 day trial access

Take a Free Trial
  • All the news that moves the needle in pharma and biotech
  • Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
  • Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More on this story...

Pharmaceutical
Opdivo drives Bristol-Myers Squibb success and helps beat estimates
27 October 2015


Company News Directory



Companies featured in this story

More ones to watch >


Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news

Today's issue

I-Mab boosts givastomig IP portfolio through Bridge Health buy
Biotechnology
I-Mab boosts givastomig IP portfolio through Bridge Health buy
18 July 2025
Biotechnology
ICER flags concerns over Scholar Rock’s apitegromab and other SMA drugs
18 July 2025
Biotechnology
Astellas links up with KISED to support Korean biotech start-ups
18 July 2025
Pharmaceutical
PwC insight into health policy and 2026 cost projections
18 July 2025
Pharmaceutical
Theranostics: the next frontier in cancer care
18 July 2025
Pharmaceutical
Kowa and Nicox sign further deal over glaucoma treatment
17 July 2025
Pharmaceutical
Allen Institute and ASAP to work on expanding brain cell atlas
17 July 2025

Company Spotlight

A Swedish biotech company developing opioid-sparing treatments for oral pain.






The Pharma Letter

39-43 Putney High Street, Putney
London, SW15 1SP
United Kingdom

  • About us
  • Contact
  • Subscribe
  • Sponsorship/advertising


  • Terms and Conditions
  • Privacy Policy
  • Twitter
  • Linkedin

Copyright © The Pharma Letter 2025   |   Headless Content Management with Blaze